

Fiscal Year 2010 Annual Review of Brovana™ (arformoterol tartrate)


Approval Criteria:

- Member must be age 18 or older
- Diagnosis of COPD, chronic bronchitis, or emphysema
- Prior trial with Advair®, Serevent®, or Foradil® within the past 45 days
- Clinical exception for members who are unable to effectively use hand-actuated devices or are stable on nebulized therapy.
- Quantity limit of 120 ml for a 30 day supply also applies.

Utilization Trends

Fiscal Year	Members	Claims	Cost	Cost/Claim	Perdiem	Units	Days
2009	8	14	\$4,113.82	\$293.84	\$9.79	1,440	420
2010	6	14	\$4,864.39	\$347.46	\$9.01	1,620	540
Percent Change	-25.00%	0.00%	18.20%	18.20%	-8.00%	12.50%	28.60%
Change	-2	0	\$750.57	\$53.62	-\$0.78	180	120

Demographics of Members Utilizing Brovana™



Prior Authorization of Brovana™

Approved	8
Denied	2
Incomplete	14
Total	24

Prescribers of Brovana™

Specialty	Claims	Cost
Pulmonary Disease Specialist	5	\$1,633.90
Family Practitioner	4	1440.52
Nurse Practitioner (Other)	3	\$1,084.49
DDSD-NFM	2	\$705.48

Recommendations

The College of Pharmacy recommends no changes at this time.